The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic
Authors:
Open Access
- 9 March 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12, 637651
Abstract
As COVID-19 cases continue to rise, it is imperative to learn more about antibodies and T-cells produced against the causative virus, SARS-CoV-2, in order to guide the rapid development of therapies and vaccines. While much of the current antibody and vaccine research focuses on the receptor-binding domain of S1, a less-recognized opportunity is to harness the potential benefits of the more conserved S2 subunit. Similarities between the spike proteins of both SARS-CoV-2 and HIV-1 warrant exploring S2. Possible benefits of employing S2 in therapies and vaccines include the structural conservation of S2, extant cross-reactive neutralizing antibodies in populations (due to prior exposure to common cold coronaviruses), the steric neutralization potential of antibodies against S2, and the stronger memory B-cell and T-cell responses. More research is necessary on the effect of glycans on the accessibility and stability of S2, SARS-CoV-2 mutants that may affect infectivity, the neutralization potential of antibodies produced by memory B-cells, cross-reactive T-cell responses, antibody-dependent enhancement, and antigen competition. This perspective aims to highlight the evidence for the potential advantages of using S2 as a target of therapy or vaccine design.Keywords
This publication has 55 references indexed in Scilit:
- The external domains of the HIV-1 envelope are a mutational cold spotNature Communications, 2015
- Virus-Specific Memory CD8 T Cells Provide Substantial Protection from Lethal Severe Acute Respiratory Syndrome Coronavirus InfectionJournal of Virology, 2014
- Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginningNature Reviews Immunology, 2013
- Expanding roles for CD4+ T cells in immunity to virusesNature Reviews Immunology, 2012
- Anti-gp41 Antibodies Cloned from HIV-Infected Patients with Broadly Neutralizing Serologic ActivityJournal of Virology, 2010
- T Cell Responses to Whole SARS Coronavirus in HumansThe Journal of Immunology, 2008
- Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV)Journal of Biomedical Science, 2005
- Identification of an HLA-A*0201–restricted CD8+ T-cell epitope SSp-1 of SARS-CoV spike proteinBlood, 2004
- A DNA vaccine induces SARS coronavirus neutralization and protective immunity in miceNature, 2004
- Kinetic screening of antibodies from crude hybridoma samples using BiacoreAnalytical Biochemistry, 2004